Naltrexone, a drug originally approved to treat opioid and alcohol dependence, has found an unexpected second life as a pain management tool when used at dramatically lower doses. At its standard dose of 50 mg, naltrexone blocks opioid receptors completely. At doses typically between 1 and 4.5 mg, it appears to work through an entirely different mechanism, calming neuroinflammation rather than simply blocking receptors. This “low-dose naltrexone” (LDN) approach has generated significant interest among patients and clinicians dealing with chronic pain conditions that respond poorly to conventional treatments, though the evidence supporting it remains a patchwork of promising signals and disappointing trials.
How a Lower Dose Changes What the Drug Does
At standard doses, naltrexone sits on opioid receptors and blocks them for most of the day, which is exactly what you want if you’re trying to prevent someone from getting high on heroin or feeling the reward from alcohol. At low doses, the drug occupies those receptors only briefly, creating a short window of blockade that the body then overcompensates for. One well-established hypothesis holds that this temporary blockade prompts the body to ramp up production of its own natural painkillers (endorphins and enkephalins) and to increase the number of opioid receptors available, creating a kind of “opioid rebound” that enhances the body’s built-in pain relief system.1PubMed Central. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
The other major mechanism involves glial cells in the brain and spinal cord. Glial cells are support cells for neurons, but when they become chronically activated, they pump out inflammatory chemicals that amplify pain signals. LDN appears to quiet these overactive glial cells, specifically by interfering with a receptor called Toll-like receptor 4 (TLR4), which is part of the innate immune system. This anti-inflammatory action seems to be unique to the low-dose range and does not occur at the standard 50 mg dose used for addiction.2PubMed. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review These two mechanisms may work in tandem: LDN both turns down central nervous system inflammation and boosts the body’s own pain-dampening chemistry.
The Fibromyalgia Evidence, and Why It Is Messy
Fibromyalgia has been the most studied pain condition for LDN, and the results illustrate the broader challenge with this drug: small positive trials keep appearing, but larger and more rigorous studies have been less convincing. A meta-analysis of randomized controlled trials found that fibromyalgia patients taking LDN had a statistically significant reduction in pain scores compared to placebo, along with a higher pressure pain threshold.3Korean Journal of Pain. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis On paper, that sounds encouraging.
But the picture gets muddier with individual trials. The INNOVA study, a year-long randomized trial in women with fibromyalgia, found that LDN did not produce a clinically meaningful benefit over placebo for pain. At three months, the placebo group actually improved more than the LDN group, and secondary outcomes showed only minor, inconsistent changes.4PubMed Central. Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study) A scoping review of the broader LDN literature found a similar split: some fibromyalgia studies reported efficacy while others concluded LDN had no clinically relevant analgesic effect.5PubMed Central. Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review
What explains the inconsistency? Fibromyalgia itself is a heterogeneous condition, meaning that patients lumped under the same diagnosis may have quite different underlying biology. It is plausible that LDN helps a subset of fibromyalgia patients, perhaps those whose pain is driven more heavily by neuroinflammation, while doing little for others. The trials conducted so far have generally been too small to tease apart subgroups convincingly. Researchers also have not yet conducted brain imaging studies comparing fibromyalgia patients before and after LDN treatment, which could help clarify which patients are most likely to respond.6Heliyon. Low dose naltrexone for the treatment of fibromyalgia: A systematic literature review
Complex Regional Pain Syndrome and Other Neuropathic Conditions
Outside fibromyalgia, the evidence for LDN in other pain conditions is thinner but occasionally striking. Complex regional pain syndrome (CRPS), a severe and often treatment-resistant condition involving burning pain, swelling, and sometimes involuntary movements, has been explored in case reports. In two patients whose CRPS had not responded to standard treatments, adding LDN to their regimen led to remission of prominent symptoms including dystonic spasms and fixed dystonia. The rationale was that CRPS involves TLR4 pathway activation and microglial involvement, making it a logical target for LDN’s anti-inflammatory mechanism.7PubMed Central. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN) A systematic review of LDN for CRPS echoed these findings, reporting that LDN treatment was positively associated with relief of chronic pain, dystonia, and sleep disturbances.8Pain Physician. Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review
Case reports and small case series are the lowest rung of clinical evidence, though. They are useful for generating hypotheses and flagging drugs worth testing in proper trials, but two patients getting better does not prove causation. For CRPS specifically, there are no published randomized controlled trials of LDN, which means the level of certainty here is still quite limited.
How LDN Compares to Existing Pain Medications
One question clinicians and patients naturally ask is how LDN stacks up against drugs already used for chronic pain, like gabapentin. A pilot randomized trial compared LDN, gabapentin, and placebo in people living with HIV who had pain and alcohol problems. All three groups saw their pain decrease over eight weeks, but none of the between-group differences were statistically significant, and none of the improvements reached established thresholds for clinical importance.9PubMed Central. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems In other words, LDN, gabapentin, and placebo all performed roughly the same in that particular population.
This is a single pilot study in a very specific group of patients, so it would be premature to conclude that LDN is no better than placebo for pain in general. But it highlights a recurring theme: LDN often does not distinguish itself clearly from placebo in controlled settings, even when uncontrolled reports and pre-post comparisons look more positive. Whether that reflects genuine inefficacy, the wrong patient populations, inadequate trial designs, or a placebo effect that chronic pain patients are particularly susceptible to remains an open question.
Ultra-Low-Dose Naltrexone Combined With Opioids
There is a separate and somewhat confusing line of research involving ultra-low-dose naltrexone, which uses amounts measured in micrograms or even picograms rather than the milligrams used in LDN. The idea here is fundamentally different from LDN as a standalone treatment. Instead of replacing opioids, ultra-low-dose naltrexone is combined with them to make them work better and prevent tolerance.
Animal studies have shown that adding tiny amounts of naltrexone to oxycodone markedly enhanced pain relief for neuropathic pain compared to oxycodone alone, while also minimizing the development of tolerance.10The Journal of Pain. Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and Associated μ-Opioid Receptor–Gs Coupling Other preclinical work found that ultra-low-dose naltrexone blocked a paradoxical pain-increasing effect of low-dose morphine, unmasking potent analgesia that was otherwise hidden. The researchers suggested this approach could allow much lower opioid doses to become clinically effective, reducing the risk of tolerance, dependence, and side effects.11PubMed. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia
This work is mostly preclinical, conducted in animal models. A combination product called Oxytrex (oxycodone plus ultra-low-dose naltrexone) went through early human trials but has not reached the market. The concept remains scientifically interesting because it addresses a real clinical problem, opioid tolerance, but it has not matured into a practical treatment option yet.
Long COVID and Pain
One of the more active areas of current LDN research involves long COVID, a condition marked by persistent fatigue, cognitive difficulties, pain, and other symptoms after a COVID-19 infection. Neuroinflammation is suspected to play a role in long COVID, which makes LDN a theoretically attractive intervention.
A systematic review and meta-analysis of LDN for long COVID pooled data from before-and-after analyses and found large effects for pain reduction and daily functioning, with moderate effects for fatigue, brain fog, and sleep quality, all favoring LDN.12PubMed Central. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis A separate study comparing LDN to physical therapy alone in long COVID patients found that LDN was associated with roughly five times the likelihood of improvement, and it helped both fatigue and pain, whereas amitriptyline (a commonly prescribed antidepressant used for chronic pain) improved only fatigue.13PubMed. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms
These results look impressive, but an important caveat applies: pre-post analyses (measuring how patients did before versus after starting a drug, without a placebo comparison group) tend to overestimate treatment effects. Long COVID symptoms fluctuate naturally, and some patients improve with time regardless of treatment. The meta-analysis authors acknowledged this limitation. Randomized controlled trials are underway, and until their results come in, the long COVID data for LDN should be treated as promising but preliminary.
Safety and Side Effects
LDN is generally considered safe, inexpensive, and well tolerated, with most clinical studies using a daily dose of 4.5 mg.14PubMed Central. Low-Dose Naltrexone: What is the Evidence? A Narrative Review That said, side effects are not rare. A retrospective study from a pain physician’s practice found that about half of patients experienced some adverse effects, most commonly nausea and fatigue, though no serious adverse effects were reported.15PubMed Central. Real-World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain: A Retrospective Cohort Study of One Pain Physician’s Practice A scoping review confirmed that adverse effects were common but mild at worst, with vivid dreams, diarrhea, and headaches topping the list, and noted that side effects often faded as patients continued treatment or adjusted their dose.16Pain Medicine. Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review
The vivid dreams side effect deserves a mention because it is so frequently reported and is distinctive to LDN. Many patients describe unusually intense or lifelike dreams, particularly in the first weeks of treatment. The dreams tend to diminish over time, and some clinicians address them by having patients take LDN in the morning rather than at bedtime.
The Critical Opioid Interaction
Perhaps the most important safety consideration is the interaction between LDN and opioid medications. Because naltrexone blocks opioid receptors, taking it while opioids are in your system can trigger precipitated withdrawal, a rapid and severe form of opioid withdrawal that comes on within minutes to hours. This is well known at standard naltrexone doses, but clinicians have sometimes assumed it would not happen at the much lower LDN doses. That assumption has been proven wrong. A published case report documented a patient on opioids for chronic pain who developed acute precipitated withdrawal with agitation, delirium, and dangerously elevated lactic acid levels after starting LDN, despite the dose being in the range previously considered safe from this risk.17Pain Medicine Case Reports. Acute Precipitated Opioid Withdrawal With Akathisia, Delirium, and Lactic Acidosis from Low-Dose Naltrexone for Chronic Pain: Case Report
This means that if you are currently taking any opioid medication, including tramadol, codeine, or any prescription painkiller in that class, starting LDN requires careful medical supervision and usually a washout period where the opioid is tapered and discontinued first. Some clinicians will start at very low doses and titrate up slowly in patients who have recently used opioids, but this is not without risk. This interaction also means LDN is not a simple add-on to existing pain regimens that include opioids.
Dosing in Practice
LDN is not commercially available at the low doses used for pain. The standard naltrexone tablet is 50 mg, so patients who use LDN get their medication from compounding pharmacies that prepare custom capsules or liquid formulations at the needed doses. This has practical implications: compounded medications are not subject to the same manufacturing standards as commercially produced drugs, costs vary widely between pharmacies, and insurance coverage is inconsistent.
Dosing protocols also vary. The most commonly studied dose is 4.5 mg daily, but some clinicians use much more gradual titration. One published protocol starts patients at 0.1 mg per day and increases by 0.1 mg every third day, continuing up to a maximum of 6.0 mg per day or until the patient finds an effective dose.18PubMed Central. Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study The rationale for this slow approach is that some patients respond at lower doses and others need more, and gradual titration helps minimize side effects. Whether this individualized dosing genuinely improves outcomes compared to a standard 4.5 mg dose has not been tested in a head-to-head trial.
Real-World Response Rates
One of the more useful pieces of data for anyone considering LDN comes from real-world practice rather than controlled trials. In a retrospective study of chronic pain patients treated by a single pain physician, about 54% reported some subjective symptom relief, most commonly improvements in pain and fatigue. Response rates varied by condition, with the highest rates seen in patients with mast cell activation syndromes and arthritis-related conditions, where about 71% reported benefit.19PubMed Central. Real-World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain: A Retrospective Cohort Study of One Pain Physician’s Practice
A roughly 50-50 split between responders and non-responders is not unusual for chronic pain treatments in general, and it reinforces the idea that LDN works for some people and not others. Unfortunately, there is no reliable way to predict in advance who will respond. There are no blood tests, imaging findings, or clinical features that have been validated as predictors of LDN response. In practice, most clinicians treat it as a therapeutic trial: try it for a few months, and if it helps, continue.
Conditions Beyond Pain Where LDN Is Used
LDN’s anti-inflammatory mechanism has led to its investigation in a range of conditions beyond chronic pain. Inflammatory bowel disease is one area where small studies have explored it, though the results have been mixed. One trial looking at whether LDN could induce remission in inflammatory bowel disease patients found that the drug did not appear to reduce inflammation through the expected pathway of dampening epithelial cell cytokine production. There were no consistent changes in key inflammatory markers between patients who responded and those who did not.20PubMed Central. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
Multiple sclerosis, Crohn’s disease, and various autoimmune conditions have all been subjects of LDN research, and a broad scoping review of the entire LDN literature found that out of 68 studies reviewed, 62 reported LDN to have some degree of efficacy, ranging from mild symptom relief to complete disease remission. The exceptions were studies finding LDN ineffective for fibromyalgia (contradicting other fibromyalgia studies that were positive), amyotrophic lateral sclerosis, and certain measures in multiple sclerosis patients.21PubMed Central. Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review That 62-out-of-68 ratio sounds impressive, but it reflects the publication bias that runs through the entire LDN literature: studies that find positive results are more likely to be published, especially small ones. The field disproportionately consists of case reports, uncontrolled studies, and small open-label trials, which are the designs most vulnerable to this bias.
Why LDN Remains Off-Label and Understudied
Naltrexone is a generic drug, which means no pharmaceutical company holds a patent on it and no company has a financial incentive to fund the large, expensive randomized trials needed for a new FDA-approved indication. Running a phase III trial for LDN in chronic pain would cost tens of millions of dollars, and the company that paid for it could not recoup that investment because any manufacturer can produce generic naltrexone. This is a familiar problem in medicine: drugs that are cheap and off-patent attract less research funding regardless of how promising they might be.
As a result, most LDN research has been funded by small grants, academic institutions, and patient advocacy organizations. The trials tend to be small, and the field advances slowly. The INNOVA trial, one of the more rigorous fibromyalgia studies, enrolled 120 patients across its two arms, which is modest by pharmaceutical trial standards. Advocates for LDN argue that the consistent signal across many small, low-quality studies amounts to something meaningful when taken as a whole. Skeptics counter that without properly powered, placebo-controlled trials, you cannot separate a genuine drug effect from the combination of placebo response, natural symptom fluctuation, and publication bias. Both camps have a point, and the honest assessment is that the evidence for LDN in pain management remains genuinely uncertain, somewhere between “interesting enough to keep investigating” and “proven enough to recommend broadly.”
Who Should Not Take LDN
Beyond the opioid interaction already discussed, LDN has a few other contraindications and cautions worth knowing about. People with active liver disease should use naltrexone cautiously at any dose, because the drug is metabolized by the liver and has carried hepatotoxicity warnings at standard doses (though liver problems have not been reported at LDN doses in the published literature). Patients taking immunosuppressive medications should discuss LDN with their prescriber, because its immune-modulating effects could theoretically interact with immunosuppressants in unpredictable ways. Pregnant and breastfeeding women are generally advised to avoid LDN due to a lack of safety data in those populations.
People who are scheduled for surgery or who may need emergency opioid pain relief should also be aware that LDN, even at low doses, can reduce the effectiveness of opioid medications given during or after a procedure. While the opioid-blocking effect of LDN wears off faster than standard-dose naltrexone, it is still relevant in acute care settings, and patients should inform their surgical and anesthesia teams that they are taking it.